IGC AMEX
IGC Pharma, Inc.
1W: -2.7%
1M: -7.1%
3M: -2.2%
YTD: -5.5%
1Y: -33.2%
3Y: -23.1%
5Y: -82.0%
$0.27
+0.00 (+1.81%)
Weekly Expected Move ±5.9%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$27.5M
52W Range0.235-0.4508
Volume629,694
Avg Volume646,712
Beta0.49
Dividend—
Analyst Ratings
Company Info
CEORam Mukunda
Employees70
SectorHealthcare
IndustryBiotechnology
IPO Date2006-05-24
Websiteigcpharma.com
10224 Falls Road
Potomac, MD 20854
US
Potomac, MD 20854
US
301 983 0998
About IGC Pharma, Inc.
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.
Latest News
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Mukunda Ram | G-Gift | 100,000 | — | 2026-09-25 |
| Mukunda Ram | G-Gift | 100,000 | — | 2026-09-25 |
| GRIMALDI CLAUDIA | G-Gift | 150,000 | — | 2026-09-25 |
| Mukunda Ram | A-Award | 2,226,475 | $0.27 | 2026-06-30 |
| GRIMALDI CLAUDIA | A-Award | 2,048,378 | $0.27 | 2026-06-30 |